Health Catalyst to Divest Vitalware for $147M, Repaying $160M Debt
HCAT sits 62% above its 52-week low of $0.955.
Summary
Health Catalyst announced it will divest its Vitalware business unit for $147 million in cash. This follows a series of significant Q4 and Q1 net losses and goodwill impairments. The company plans to use the proceeds, combined with cash on hand, to fully repay its existing senior secured term loan facility of approximately $160 million. This divestiture, valued at 1.5 times the company's current market cap, significantly strengthens the balance sheet and allows for a sharper strategic focus on core AI and technology investments. The transaction is expected to close in 2026.
At the time of this announcement, HCAT was trading at $1.55 on NASDAQ in the Technology sector, with a market capitalization of approximately $98.3M. The 52-week trading range was $0.96 to $4.29. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.